Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q1 FY25 results · Apr–Jun 2024
Lincoln Pharmaceuticals reported revenue from operations of ₹147.28 crore (up 8.6% from Q1 FY24) and net profit of ₹23.67 crore (up 24.5% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 147.28 | 135.62 | +8.6% | 142.49 | +3.4% |
| Other income | 10.41 | 7.69 | +35.3% | 7.02 | +48.3% |
| Total income | 157.69 | 143.31 | +10.0% | 149.51 | +5.5% |
| Profit before tax | 29.48 | 25.45 | +15.8% | 22.22 | +32.7% |
| Net profit for the period | 23.67 | 19.01 | +24.5% | 18.60 | +27.3% |
| EPS, basic (₹) | 11.82 | 9.49 | +24.6% | 9.28 | +27.4% |
| Net margin (%) | 16.1 | 14.0 | 13.1 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 147.28 | 135.62 | +8.6% | 142.49 | +3.4% |
| Other income | 10.41 | 7.69 | +35.3% | 7.02 | +48.3% |
| Total income | 157.69 | 143.31 | +10.0% | 149.51 | +5.5% |
| Profit before tax | 29.48 | 25.45 | +15.8% | 22.22 | +32.7% |
| Net profit for the period | 23.67 | 19.01 | +24.5% | 18.60 | +27.3% |
| EPS, basic (₹) | 11.82 | 9.49 | +24.6% | 9.28 | +27.4% |
| Net margin (%) | 16.1 | 14.0 | 13.1 |
Consolidated
- Filed with BSE
- 23 Aug 2024, 11:41 IST
- Board meeting
- 08 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Aug 2024, 11:41 IST
- Board meeting
- 08 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE